Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
- IND Accepted in April by the U.S. FDA for MCLA-158 -
UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States.
MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptors (EGFR). MCLA-158 was identified from a large library of bispecific antibodies targeting molecules belonging to the Wnt and receptor tyrosine kinase signaling pathways as part of work performed by the suppresSTEM consortium, a project that was funded by the European Union. Functional evaluation of patient-derived colorectal tumors, including those harboring RAS and/or PI3K mutations, demonstrated that MCLA-158 was more effective at inhibiting tumor growth and promoting apoptosis than an approved targeted therapy comparator for metastatic colorectal cancer, cetuximab. In preclinical studies, Merus also observed that the growth inhibitory activity of MCLA-158 was greater for colon tumors compared to normal colon tissue, consistent with its good safety profile in non-human primates.
"The commencement of our Phase 1 clinical trial of MCLA-158 is an important milestone for the advancement of our pipeline of bispecific antibodies obtained from our Biclonics® technology platform," said Ton Logtenberg, Ph.D., Chief Executive Officer. "We believe MCLA-158 has the potential to address features that limit currently approved colorectal cancer-targeted therapies, including issues with off-target toxicity and inability to target tumor stem cells, and thus, potentially treat a broader population of patients more effectively."
The Phase 1, open-label, multicenter clinical trial of MCLA-158 consists of two parts, a dose escalation and a dose expansion. The dose escalation part is intended to determine the appropriate dose of MCLA-158. The dose expansion part will evaluate the safety and tolerability of the defined dose of MCLA-158 in patients with solid tumors. The dose escalation and expansion parts of the trial will also examine the preliminary antitumor activity of single-agent MCLA-158.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Additional pipeline programs include MCLA-117, which is currently being studied in a Phase 1 clinical trial in patients with acute myeloid leukemia, and MCLA-158, a Biclonics® being studied in a Phase 1 clinical trial in patients with solid tumors with an initial focus on metastatic colorectal cancer. Through its collaboration with Incyte Corporation, Merus is also developing a preclinical bispecific antibody designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. For additional information, please visit Merus' website, www.merus.nl.
The suppresSTEM consortium consisted of Merus N.V. as coordinator, The Hubrecht Institute (The Netherlands), OcellO B.V. (The Netherlands), Institute for Research in Biomedicine (IRB, Barcelona Spain), and The Wellcome Trust Sanger Institute (UK). The research leading to the results described here received funding from the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement n° 601876. In May 2013 the consortium was granted a total of about €6 million to develop novel antibody-based therapeutics targeting cancer stem cells for the treatment of colorectal cancer as well as patient-derived organoid-based screening tools to aid drug discovery as a European Union's FP7 program. Specifically, the consortium was focused on addressing mechanisms that lead to the development of treatment resistance and tumor escape in colon cancer, a problem that has hampered the development of efficient therapeutics in the past. Furthermore, it pioneered the application of patient-derived tissue in drug discovery to address the high clinical failure rate in cancer drug research.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential or promise of Merus' platform for generating bispecific antibodies and their development, the design, treatment potential, clinical development and clinical development plans for Merus' bispecific antibody therapeutic candidates, the advancement of the Phase I clinical trial in Europe for MCLA-158, the plan to open sites for a Phase 1 MCLA-158 trial in the United States, the treatment potential of MCLA-158 compared to other approved targeted therapies such as cetuximab in humans, the design of our Phase 1, open-label, multicenter clinical trial of MCLA-158 to determine the appropriate dose of MCLA-158, the planned expansion phase to evaluate the safety and tolerability of the defined dose of MCLA-158 in patients with solid tumors, the plan to examine the preliminary antitumor activity of single-agent MCLA-158, and the suppresSTEM consortium's ability to address mechanisms that lead to the development of treatment resistance and tumor escape in colon cancer, and ability to use patient-derived tissue in drug discovery to address the clinical failure rate in cancer drug research.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in existing and potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 30, 2018, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Ondot Announces Investment from Citi Ventures to Power Enriched Transactions22.10.2018 17:00 | Pressemelding
The investment will fuel Ondot’s international growth and give cardholders accessing info via Ondot’s platform increased control over and visibility into each transaction Santa Clara, Ca, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ondot Systems, the global leader in mobile payments services, today announced that it has secured a strategic funding investment from Citi Ventures. Ondot works directly with financial institutions to give consumers increased control over and visibility into their personal payment transactions. With Ondot, consumers can manage functions such as fraud alerts, transaction limits and purchase location restrictions, all from the convenience of an app on their smartphone or desktop. This investment will further support Ondot’s efforts to grow its international presence and product offerings. Today’s digitally connected consumers are looking for more ways to access detailed information about their digital lives — including personal payment transactions. Ondot’s platform add
Auth0 Supports Global Growth with Office Expansions in US and UK22.10.2018 15:00 | Pressemelding
New offices accommodate rapid employee growth and reinforce customer commitment BELLEVUE, Wash. and LONDON, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Auth0, a global leader in Identity-as-a-Service (IDaaS), today announced it has moved into larger offices in Bellevue, WA, and London, UK, to accommodate current and future growth. The company’s headquarters in Bellevue has experienced an upsurge in employees over the past year, signalling its continued growth trajectory in the region. Recently named a Gold winner in the Seattle Business Tech Impact awards, along with additional industry recognition as a great place to work, Auth0 is attracting top talent in the area. The new office occupies the entire 6th floor of the U.S. Bank Plaza, located at 10800 NE 8th St. The new London office at 182-194 Union St. is a former Victorian-style warehouse, located in the South Bank district. This opening also launches the new “Auth0 Identity Centre,” a 50-seat event space where the company will host customers
Mitratech Announces TeamConnect Essentials for Mid-Sized Legal Departments22.10.2018 15:00 | Pressemelding
New SaaS Legal Operations Solution Can Save $250,000 Per Year in Staff Time Savings and Reduced Legal Spend AUSTIN, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Mitratech today announced the launch of TeamConnect Essentials, an easy-to-use, quick-to-implement SaaS legal operations solution designed for legal departments who want to leverage built-in best practices validated by 30 years of Mitratech’s client experience. Essentials is built on Mitratech’s TeamConnect platform and acts as a central hub for all legal operations, including integrated matter management, outside counsel management, e-Billing, Microsoft® Office integration, and reporting, delivered as an adaptable, cloud-based solution. “Thirty percent of FORTUNE 500 companies currently use TeamConnect as a platform for legal department innovation. We’ve taken our experience with those customers and others, coupled it with a streamlined implementation program, and created a unique solution for legal departments earlier in their tr
Paysafe’s Differentiated Solutions and Customer Service Recognized by Independent Research Firm22.10.2018 15:00 | Pressemelding
Recently Published Report Also Acknowledges its Bold Strategy and Vision LONDON, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Paysafe Group (“Paysafe”), a leading global payments provider, has been named a ‘Strong Performer’ in a recently published third party report: The Forrester Wave™: Global Merchant Payment Providers, Q4 2018. In the report, Forrester acknowledges Paysafe’s bold strategy and vision and gives it the highest possible score in the omnichannel solution criterion. It also describes Paysafe as a “best fit for merchants that are positioned to take advantage of its many value-added services and consumer businesses” and states that the Paysafe product offering “is one of the most differentiated solution value propositions” of any provider in the report. The Forrester report also comments on Paysafe’s customer service focus, stating client references “were extremely pleased with Paysafe’s transparency and customer service.” Joel Leonoff, President and CEO, Paysafe Group, commented: “W
INVEX partners with Ondot to Launch the First Instant Digital Card in México22.10.2018 14:00 | Pressemelding
Solution accelerates digital transformation, acquisition and use of payment methods in México Santa Clara, California and Mexico City, Mexico, Oct. 22, 2018 (GLOBE NEWSWIRE) -- INVEX (BMV: INVEX A) Credit Card business, the only monoliner specializing in payments and cobranded cards, with focus on 100% digital customer experience in Mexico, has partnered with Ondot, the global leader in mobile payments services, to deliver full card life-cycle management associated with the ‘Instant Card’ on a single platform. The digital card services solution creates an end-to-end customer journey -from product presentment, selection, digital acquisition to instant issuance and secure payments. Conversational platforms are becoming the new digital banking user interface. As consumers spend more time on messaging apps, IoT devices and social media, they require similar solutions from their financial institutions. INVEX solution is built on Ondot’s mobile card services conversational platform and creat
Spartan Essential Turn-Key Design Significantly Reduces Time-to-Market for Equipment Manufacturers22.10.2018 14:00 | Pressemelding
Compact Design with Exceptional Wi-Fi Performance SAN JOSE, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ: QTNA), the innovator and global leader of high-performance Wi-Fi solutions, has introduced Spartan Essential, a fast to market turn-key design to address multiple consumer Wi-Fi applications such as mesh, access point for wired extenders and simple boosters for upgrading existing gateway wireless LANs. This new compact product eliminates the need for lengthy feature developments, testing and qualification by Original Equipment Manufacturers (OEMs), Original Design Manufacturers (ODMs) and software integrators. Spartan Essential is a complete turn-key design that uses Quantenna’s award-winning QSR1000 Wave 2 chipset solution and supports dual-band dual-concurrent 4x4 802.11ac and 2x2 802.11n. The Spartan Essential design offers the following advantages: Compact and aesthetic industrial design High-performance internal antennas Single PCB design fo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom